May 12, 2020 / 12:49 AM / 2 months ago

BRIEF-Adamis Says Reacquiring From Sandoz Rights To Symjepi Products

May 11 (Reuters) - Adamis Pharmaceuticals Corp:

* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON SYMJEPI PRODUCTS AND ANNOUNCES DISTRIBUTION AND COMMERCIALIZATION AGREEMENT FOR SYMJEPI AND ZIMHI PRODUCTS

* ADAMIS PHARMACEUTICALS -REACQUIRING FROM SANDOZ INC. RIGHTS TO SYMJEPI INJECTION 0.3MG, INJECTION 0.15MG PRODUCTS CURRENTLY MARKETED, AVAILABLE IN US

* ADAMIS PHARMACEUTICALS- AS PART OF TERMINATION AGREEMENT, SANDOZ WILL CONTINUE TO SUPPORT PRODUCTS IN U.S. UNDER EXISTING COMMERCIALIZATION AGREEMENT

* ADAMIS-ENTERED INTO EXCLUSIVE DISTRIBUTION & COMMERCIALIZATION AGREEMENT WITH US WORLDMEDS FOR US COMMERCIAL RIGHTS FOR SYMJEPI, ZIMHI PRODUCTS

* ADAMIS-WILL RETAIN RIGHTS TO COMMERCIALIZE PRODUCTS OUTSIDE U.S., MAY CONTINUE TO DEVELOP ITS INJECTION PLATFORM FOR ADDITIONAL PRODUCT CANDIDATES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below